시장보고서

상품코드

1555690

세계의 강심제 시장 : 약물 유형별, 용도별, 유통별, 투여경로별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Cardiotonic Agents Market, By Drug Type, By Application, By Distribution, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 08월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 376 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

강심제 시장 규모는 2023년 8억 7,898만 달러로 2024년부터 2032년까지 21.5%의 복합 연간 성장률(CAGR)로 확대될 전망입니다.

강심제 시장 : 시장 역학

약믈 제제의 혁신과 신규강심제의 개발이 강심제 시장의 요구를 견인할 전망입니다.

약물 제제의 혁신과 새로운 강심제 시장 개척이 강심제 시장을 크게 견인하고 있습니다. 약리학과 생명공학의 발전으로 보다 효과적이고 표적화된 강심제가 개발되어 치료 효과가 향상되고 부작용이 감소하고 있습니다. 방출 제어 시스템 및 병용 요법과 같은 약물 전달을 개선하는 새로운 제형은 강심제의 범위를 더욱 확대하고 있습니다. 이러한 혁신은 심혈관 질환에 대한 보다 개인화되고 효과적인 치료에 대한 수요 증가에 대응하고 있습니다. 게다가 새로운 화합물과 메커니즘에 대한 지속적인 연구는 차세대 강심제에 대한 길을 열고 암멧 의료 요구를 충족시키고 심장 질환을 가진 환자에게 새로운 희망을 가져다줍니다. FDA와 EMA와 같은 규제기관이 획기적인 혁신에 신속한 길을 제공함으로써 새로운 제제의 승인률이 상승하고 있습니다. 혁신적인 제형을 포함한 임상시험의 수가 증가하고 있습니다. 예를 들어, 2023년에는 신규 약물 전달 시스템과 제형에 대해 1, 000건 이상의 임상시험이 시작되었습니다.

강심제 시장 : 주요 인사이트

우리의 리서치 애널리스트가 공유한 분석에 따르면 시장은 예측 기간 동안에 약 21.5%의 복합 연간 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

약물 유형별 세분화는 심장 배당체가 2023년에 가장 큰 시장 점유율을 나타낼 것으로 예측됩니다.

용도별로는 울혈성 심부전이 2023년의 주요 유형이었습니다.

유통 부문별로 2023년에는 소매 약국이 주요 유형이었습니다.

최종 사용자 세분화를 기반으로 2023년에는 병원이 주요 유형이었습니다.

지역별로는 북미가 2023년 수익으로 이끌었습니다.

강심제 시장 : 세분화 분석 :

세계의 강심제 시장은 약물 유형, 용도, 유통, 투여 경로, 최종 사용자, 지역에 따라 세분화됩니다.

시장은 의약품 유형에 따라 네 가지 범주로 나뉩니다. 걱정당, 교감 신경 자극제, 포스 포디 에스테라아제 억제제, 칼슘 채널 차단제입니다. 디곡신과 같은 약물을 함유하는 디기탈리스 배당체는 심장 수축을 강화하기 위해 심방 세동 및 심부전 치료에 자주 사용됩니다. 다양한 비타민과 항산화제는 심근 보호제로 알려진 다양한 유형의 물질의 예이며 심근을 상해로부터 보호함으로써 기능하며 심근 경색과 수술 중에 자주 사용됩니다. 도부타민과 같은 교감 신경 자극제는 교감 신경계의 활성화 효과를 시뮬레이션하여 급성 심부전의 심장 성능을 향상시키는 데 사용됩니다.

시장은 최종 사용자에 의해 네 가지 범주로 나뉩니다: 병원, 외래수술센터(ASC), 전문 클리닉, 재택치료의 4개. 병원 약국은 의료 시설에 강심제를 직접 공급하고 심각한 환자가 시간에 따라 치료 계획에 따라 처방전을 받도록 보장하기 위해이 시장에서 중요한 역할을합니다. 이 약국은 심각한 환자를 긴급하게 치료할 필요가 있기 때문에 많은 양의 약물을 다루는 경우가 많습니다. 소매 약국에서는 장기적으로 강심제를 필요로 하는 환자를 위해 병원 이외에도 일상적으로 사용할 수 있는 상품을 많이 보유하고 있습니다. 온라인 약국은 환자가 집에 머물면서 강심제를 얻을 수있는 편의성에서 큰 성장을 이루고 있습니다. 온라인 약국은 합리적인 가격 설정과 풍부한 구색을 자주 제공하며 택배의 이점도 있습니다.

강심제 시장 : 지리적 인사이트

북미에서는 강심제 시장은 주로 미국과 캐나다가 견인하고 있습니다. 미국은 선진적인 헬스케어 인프라를 가지고 있으며 심혈관 질환의 유병률이 높고 연구개발에 힘을 쏟고 있기 때문에 최대의 공헌국이 되고 있습니다. 미국은 의료 제공자의 네트워크가 확립되어 있어 새로운 의료기술과 치료법의 채용률이 높다는 장점이 있습니다. 캐나다는 또한 종합적인 건강 관리 시스템과 심혈관 연구에 대한 투자 확대로 중요한 역할을 하고 있습니다. 양국 모두 고령화 사회에서 심장 관련 질환의 이환율 상승에 대응하기 때문에 혁신적인 강심제에 대한 수요가 높습니다. 또한, 이들 국가의 규제 지원과 유리한 상환 상황은 시장 성장을 더욱 자극하고 있습니다. 전반적으로, 북미의 강심제 시장은 견조한 시장 개척, 심장혈관 건강에 대한 많은 투자, 치료 혁신에 대한 첨단 접근법을 특징으로 합니다.

강심제 시장 : 경쟁 구도:

강심제 시장에는 시장 점유율을 다투는 유력 기업이 여러 개 존재합니다. 이 분야의 주요 기업은 Pfizer, Merck & Co., Novartis 등의 다국적 제약 대기업을 포함하며, 이들 기업은 광범위한 R&D 능력을 활용하여 강심 요법을 추진하고 있습니다. 이 회사들은 심부전 및 기타 심장 질환을 목표로 하는 혁신적인 신약 개발에 착수하여 환자의 예후 개선과 시장 확대를 목표로 하고 있습니다. 게다가 Amgen과 Gilead Sciences와 같은 소규모의 전문성이 있는 생명공학 기업도 틈새 치료 영역과 맞춤형 의료 접근법에 중점을 두고 이 분야에서 활약하고 있습니다. 경쟁은 신규 강심약의 개발을 가속화하는 것을 목적으로 하는 제약회사와 연구기관과의 지속적인 제휴 및 공동연구에 의해 더욱 격화되고 있습니다. 시장이 발전함에 따라, 각 회사는 신흥 시장에서의 사업 기회를 모색하고, 디지털 헬스 솔루션 등의 첨단 기술을 활용하여 강심제 치료의 유효성과 접근성을 높이고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석-강심제 업계

경쟁 대시보드
기업 프로파일
- Novartis International AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Sanofi SA
- Boehringer Ingelheim GmbH
- Eli Lilly and Company
- AstraZeneca plc
- Johnson &Johnson
- Merck &Co., Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Roche Holding AG
- Teva Pharmaceutical Industries Ltd.
- Mylan NV
- AbbVie Inc.
- Others

제14장 애널리스트의 전방위 전망

BJH 24.10.11

REPORT HIGHLIGHT

Cardiotonic Agents Market size was valued at USD 878.98 million in 2023, expanding at a CAGR of 21.5% from 2024 to 2032.

The cardiotonic agents market is focused on medications that enhance the force of cardiac contraction, improving heart function in patients with heart failure or other cardiovascular conditions. These agents, which include positive inotropes such as digoxin, dobutamine, and milrinone, are essential for managing severe heart conditions and are used in both acute and chronic settings. The market is influenced by factors such as the rising prevalence of heart disease, advancements in drug formulations, and growing awareness of heart health. Innovations in drug delivery systems and a push for personalized medicine are driving growth, while challenges include the need for careful management of side effects and potential interactions with other medications. Regulatory approvals and ongoing research into new cardiotonic agents also play significant roles in shaping the market landscape.

Cardiotonic Agents Market- Market Dynamics

Innovations in drug formulations and the development of new cardiotonic agents driving the need for the cardiotonic agents market

Innovations in drug formulations and the development of new cardiotonic agents are significantly driving the cardiotonic agents market. Advances in pharmacology and biotechnology have led to the creation of more effective and targeted cardiotonic drugs, enhancing their therapeutic efficacy and reducing side effects. Novel formulations that improve drug delivery, such as controlled-release systems and combination therapies, are further expanding the scope of cardiotonic agents. These innovations cater to the growing demand for more personalized and effective treatments for cardiovascular diseases. Additionally, ongoing research into novel compounds and mechanisms is paving the way for the next generation of cardiotonic agents, addressing unmet medical needs and offering new hope for patients with heart conditions. The approval rate for new formulations has increased, with regulatory agencies like the FDA and EMA providing expedited pathways for breakthrough innovations. The number of clinical trials involving innovative formulations has been rising. For instance, in 2023, over 1,000 clinical trials were initiated for novel drug delivery systems and formulations.

Cardiotonic Agents Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 21.5% over the forecast period (2024-2032)

Based on drug type segmentation, Cardiac Glycosides was predicted to show maximum market share in the year 2023

Based on application segmentation, Congestive Heart Failure was the leading type in 2023

Based on distribution segmentation, Retail Pharmacies was the leading type in 2023

Based on end user segmentation, Hospitals were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Cardiotonic Agents Market- Segmentation Analysis:

The Global Cardiotonic Agents Market is segmented based on Drug Type, Application, Distribution, Route of Administration, End User, and Region.

The market is divided into four categories based on drug type: Cardiac Glycosides, Sympathomimetic Agents, Phosphodiesterase Inhibitors, and Calcium Sensitizers. Digitalis Glycosides, which include medications such as digoxin, are frequently used to treat atrial fibrillation and heart failure because they strengthen cardiac contractions. Various vitamins and antioxidants are examples of the varied class of substances known as cardioprotectants, which function by shielding the heart muscle from injury and are frequently utilized during myocardial infarctions or surgery. Sympathomimetic agents, such as dobutamine, are used to improve cardiac performance in acute heart failure by simulating the effects of sympathetic nervous system activation.

The market is divided into four categories based on end users: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Homecare Settings. Hospital pharmacies play a vital role in this market since they supply cardiotonic agents directly to healthcare facilities, guaranteeing that patients who are severely ill receive their prescriptions on time and according to their treatment plans. These pharmacies frequently handle larger amounts of these medications because of the urgent requirements of patients receiving critical care. Retail pharmacies provide a large selection of goods for routine usage outside of hospital settings, catering to patients who require cardiotonic agents on a long-term basis. Because they are convenient and let patients obtain cardiotonic drugs from the comfort of their homes, online pharmacies have experienced substantial growth. In addition to frequently offering reasonable pricing and a large assortment of products, they provide the benefit of home delivery.

Cardiotonic Agents Market- Geographical Insights

In North America, the cardiotonic agents market is predominantly driven by the United States and Canada, with the U.S. being the largest contributor due to its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and strong emphasis on research and development. The U.S. benefits from a well-established network of healthcare providers and a high rate of adoption of new medical technologies and treatments. Canada also plays a significant role, bolstered by its comprehensive healthcare system and growing investment in cardiovascular research. Both countries experience a high demand for innovative cardiotonic agents as they address the rising incidence of heart-related conditions among ageing populations. Additionally, regulatory support and a favorable reimbursement landscape in these countries further stimulate market growth. Overall, the North American market for cardiotonic agents is characterized by robust development, significant investment in cardiovascular health, and a progressive approach to treatment innovations.

Cardiotonic Agents Market- Competitive Landscape:

The Cardiotonic Agents market includes several prominent players vying for market share. Key companies in this sector include multinational pharmaceutical giants such as Pfizer, Merck & Co., and Novartis, which leverage their extensive research and development capabilities to advance cardiotonic therapies. These firms are engaged in the development of new and innovative drugs that target heart failure and other cardiac conditions, aiming to improve patient outcomes and expand market reach. Additionally, smaller, specialized biotechnology firms like Amgen and Gilead Sciences are also active in this space, focusing on niche therapeutic areas and personalized medicine approaches. The competition is further intensified by ongoing collaborations and partnerships between pharmaceutical companies and research institutions, aimed at accelerating the development of novel cardiotonic agents. As the market evolves, companies are also exploring opportunities in emerging markets and leveraging advanced technologies, such as digital health solutions, to enhance the effectiveness and accessibility of cardiotonic treatments.

Recent Developments:

In February 2022, Roche announced positive results from phase 3 clinical trials of the heart failure drug, furosemide which reduces the fluid buildup in the body and improves cardiac function.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CARDIOTONIC AGENTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Novartis International AG
Pfizer Inc.
GlaxoSmithKline plc
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
AstraZeneca plc
Johnson & Johnson
Merck & Co., Inc.
Amgen Inc.
Bristol-Myers Squibb Company
Roche Holding AG
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
AbbVie Inc.
Others

GLOBAL CARDIOTONIC AGENTS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Cardiac Glycosides
Sympathomimetic Agents
Phosphodiesterase Inhibitors
Calcium Sensitizers

GLOBAL CARDIOTONIC AGENTS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Congestive Heart Failure
Cardiogenic Shock
Acute Myocardial Infarction
Others

GLOBAL CARDIOTONIC AGENTS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacie

GLOBAL CARDIOTONIC AGENTS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous
Intramuscular
Subcutaneous

GLOBAL CARDIOTONIC AGENTS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Homecare Settings

GLOBAL CARDIOTONIC AGENTS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Cardiotonic Agents Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Cardiotonic Agents Market Snippet by Drug Type
- 2.1.2. Cardiotonic Agents Market Snippet by Application
- 2.1.3. Cardiotonic Agents Market Snippet by Distribution
- 2.1.4. Cardiotonic Agents Market Snippet by Route of Administration
- 2.1.5. Cardiotonic Agents Market Snippet by End User
- 2.1.6. Cardiotonic Agents Market Snippet by Country
- 2.1.7. Cardiotonic Agents Market Snippet by Region
2.2. Competitive Insights

3. Cardiotonic Agents Key Market Trends

3.1. Cardiotonic Agents Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Cardiotonic Agents Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Cardiotonic Agents Market Opportunities
3.4. Cardiotonic Agents Market Future Trends

4. Cardiotonic Agents Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Cardiotonic Agents Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Cardiotonic Agents Market Landscape

6.1. Cardiotonic Agents Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Cardiotonic Agents Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 7.1.2. Cardiac Glycosides
- 7.1.3. Sympathomimetic Agents
- 7.1.4. Phosphodiesterase Inhibitors
- 7.1.5. Calcium Sensitizers

8. Cardiotonic Agents Market - By Application

8.1. Overview
- 8.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
- 8.1.2. Congestive Heart Failure
- 8.1.3. Cardiogenic Shock
- 8.1.4. Acute Myocardial Infarction
- 8.1.5. Others

9. Cardiotonic Agents Market - By Distribution

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution, 2023 & 2032 (%)
- 9.1.2. Hospital Pharmacies
- 9.1.3. Retail Pharmacies
- 9.1.4. Online Pharmacie

10. Cardiotonic Agents Market - By Route of Administration

10.1. Overview
- 10.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
- 10.1.2. Oral
- 10.1.3. Intravenous
- 10.1.4. Intramuscular
- 10.1.5. Subcutaneous

11. Cardiotonic Agents Market - By End User

11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 11.1.2. Hospitals
- 11.1.3. Ambulatory Surgical Centers
- 11.1.4. Specialty Clinics
- 11.1.5. Homecare Settings

12. Cardiotonic Agents Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Cardiotonic Agents Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Cardiotonic Agents Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.10. Italy
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.10.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.10.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.10.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.11. United Kingdom
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.11.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.11.5. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.11.6. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.7. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.12. France
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.12.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.12.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.12.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.13. Russia
  - 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.13.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.14. Netherlands
  - 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.14.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.14.4. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.14.5. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.6. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.16. Poland
  - 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.16.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.17. Rest of Europe
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Cardiotonic Agents Key Manufacturers in Asia Pacific
- 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 12.4.7. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.8. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9. India
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.9.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.9.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.10. China
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.10.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.10.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.10.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.14. Thailand
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.15. Indonesia
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America
- 12.5.1. Overview
- 12.5.2. Cardiotonic Agents Key Manufacturers in Latin America
- 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.5.6. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 12.5.7. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.8. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Cardiotonic Agents Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Cardiotonic Agents Industry

13.1. Competitive Dashboard
13.2. Company Profiles
- 13.2.1. Novartis International AG
- 13.2.2. Pfizer Inc.
- 13.2.3. GlaxoSmithKline plc
- 13.2.4. Sanofi S.A.
- 13.2.5. Boehringer Ingelheim GmbH
- 13.2.6. Eli Lilly and Company
- 13.2.7. AstraZeneca plc
- 13.2.8. Johnson & Johnson
- 13.2.9. Merck & Co., Inc.
- 13.2.10. Amgen Inc.
- 13.2.11. Bristol-Myers Squibb Company
- 13.2.12. Roche Holding AG
- 13.2.13. Teva Pharmaceutical Industries Ltd.
- 13.2.14. Mylan N.V.
- 13.2.15. AbbVie Inc.
- 13.2.16. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us